Latest Articles

Publication Date
Opiranserin (VVZ-149): what's new in analgesics.

Opiranserin (VVZ-149) is a novel non-opioid, non-steroidal intravenous analgesic with triple antagonistic activity at glycine transporter 2 (GlyT2), purine 2 receptor 3 (P2X3), and serotonin receptor (5-HT2A). Its half-maximal inhibitory …

Published: Oct. 2, 2026, midnight
The 'missed disease' that affects 190 million: endometriosis drug shows early promise.

Published: Oct. 1, 2026, midnight
The Most Impactful Symptom of Endometriosis Questionnaire (MISE-Q): a cognitive interview study.

Endometriosis is a condition with symptoms that vary widely, often affecting daily activities and quality of life. A patient-centered approach to identifying and measuring the most important symptoms has been …

Published: Sept. 30, 2026, midnight
Mesonephric and Mesonephric-Like Proliferations of the Gynecologic Tract.

Mesonephric remnants are vestiges of Wolffian ducts located adjacent to the Müllerian ducts. Proliferations arising from these remnants are uncommon and classified as benign, including mesonephric hyperplasia, Gartner and rete …

Published: Sept. 30, 2026, midnight
Comparison of perioperative outcomes between laparoscopy and robotic-assisted surgery in the surgical treatment of endometriosis: a retrospective study.

Minimally invasive surgery is the gold standard for the surgical treatment of endometriosis. However, controversy remains in the literature regarding the perioperative benefits of robotic-assisted surgery compared to laparoscopic surgery, …

Published: Sept. 28, 2026, midnight
Simvastatin and Primaquine Identified as Potential Endometriosis Therapeutics via a Novel Epithelial-Stromal Assembloid Drug Screening Assay.

Endometriosis is an estrogen-driven, inflammatory disorder affecting ~10% of menstruators, causing severe pain. Current treatments that reduce estrogen or inflammation have inconsistent efficacy and poor tolerability. Therapies identified via drug-repositioning …

Published: Sept. 27, 2026, midnight
Artificial intelligence for women's reproductive health: A scoping review of global diagnostic trends, methodological gaps, and a translational research agenda for low-resource settings.

Women's reproductive and endocrine disorders including Polycystic Ovary Syndrome (PCOS), endometriosis, thyroid disorders, infertility, and pregnancy-related complications remain a major global health burden. These conditions are especially difficult to manage …

Published: Sept. 25, 2026, midnight
YTHDF3 promotes angiogenesis in endometriosis by enhancing the translation efficiency of PFKFB3.

Angiogenesis plays a critical role in the progression of endometriosis, with enhanced glycolysis accelerating pathological angiogenesis. Prior research has identified a central role for N6-methyladenosine (m6A) modification in regulating glycolytic …

Published: Sept. 23, 2026, midnight
Establishment of pathology-validated immortalized patient-derived ovarian endometriosis epithelial cell line.

Endometriosis is a heterogeneous gynecological disorder for which experimental model development is often limited by diagnostic ambiguity and the restricted lifespan of primary epithelial cultures. Although immortalization strategies enable long-term …

Published: Sept. 23, 2026, midnight
Thyroid Autoimmunity and Reproductive Outcomes: Antibody-Specific Associations in a National Cohort from the All of Us Research Program.

Thyroid autoimmunity (TAI) is the most common autoimmune condition affecting women of reproductive age. Prior studies have linked TAI to adverse reproductive outcomes; however, antibody-specific effects and their relative clinical …

Published: Sept. 22, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!